YUN C YEN

Summary

Affiliation: City of Hope National Medical Center
Country: USA

Publications

  1. doi request reprint Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
    Shikha Gaur
    Department of Molecular Pharmacology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Mol Cancer 13:21. 2014
  2. doi request reprint Wnt modulates MCL1 to control cell survival in triple negative breast cancer
    Lixin Yang
    Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Beckman Building, Room 4117, 1500 East Duarte Road, Duarte, CA 91010, USA
    BMC Cancer 14:124. 2014
  3. ncbi request reprint The utility of tumor-specifically internalizing peptides for targeted siRNA delivery into human solid tumors
    Frank Un
    Department of Molecular Pharmacology, Beckman Research Institute of City of Hope National Medical Center, Duarte, CA, USA
    Anticancer Res 32:4685-90. 2012
  4. ncbi request reprint Markers for efficacy of mammalian target of rapamycin inhibitor
    Yu Min Liao
    Division of Medical Oncology and Hematology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan, ROC
    Anticancer Res 32:4235-44. 2012
  5. pmc De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer
    Xiwei Wu
    Department of Cancer Biology, City of Hope Beckman Research Institute, 1500 Duarte Road, Duarte, CA 91010, USA
    J Transl Med 10:42. 2012
  6. pmc Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms
    Shikha Gaur
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Mol Cancer 7:46. 2008
  7. pmc Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
    Keqiang Zhang
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Mol Cancer 8:11. 2009
  8. pmc An overview of the rare parotid gland cancer
    Kimberley Ho
    Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
    Head Neck Oncol 3:40. 2011
  9. pmc Mammalian target of rapamycin and head and neck squamous cell carcinoma
    Yu Min Liao
    Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
    Head Neck Oncol 3:22. 2011
  10. pmc Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer
    Stella Tommasi
    Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Breast Cancer Res 11:R14. 2009

Detail Information

Publications71

  1. doi request reprint Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status
    Shikha Gaur
    Department of Molecular Pharmacology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Mol Cancer 13:21. 2014
    ..To evaluate the therapeutic effect, we combined Dovitinib, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases with chemotherapeutic drug, oxaliplatin in preclinical models of colon cancer...
  2. doi request reprint Wnt modulates MCL1 to control cell survival in triple negative breast cancer
    Lixin Yang
    Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Beckman Building, Room 4117, 1500 East Duarte Road, Duarte, CA 91010, USA
    BMC Cancer 14:124. 2014
    ..Therefore, we directed our focus on identifying the WNT ligand and its underlying mechanism in TNBC cells...
  3. ncbi request reprint The utility of tumor-specifically internalizing peptides for targeted siRNA delivery into human solid tumors
    Frank Un
    Department of Molecular Pharmacology, Beckman Research Institute of City of Hope National Medical Center, Duarte, CA, USA
    Anticancer Res 32:4685-90. 2012
    ..A Phase I clinical trial demonstrated its therapy potential. HN-1 represents a tumor-specifically internalizing peptide for targeted-drug delivery into human head and neck squamous cell carcinoma...
  4. ncbi request reprint Markers for efficacy of mammalian target of rapamycin inhibitor
    Yu Min Liao
    Division of Medical Oncology and Hematology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan, ROC
    Anticancer Res 32:4235-44. 2012
    ..We discuss these potential markers in terms of selection of candidates, baseline expression, pathway inhibition and source of targeted protein...
  5. pmc De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer
    Xiwei Wu
    Department of Cancer Biology, City of Hope Beckman Research Institute, 1500 Duarte Road, Duarte, CA 91010, USA
    J Transl Med 10:42. 2012
    ..Discovery profiling of circulating small RNAs has not been reported in breast cancer (BC), and was carried out in this study to identify blood-based small RNA markers of BC clinical outcome...
  6. pmc Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms
    Shikha Gaur
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Mol Cancer 7:46. 2008
    ..Studies in rodents indicate that optimal ratios of CEACAM1 splice variants are required to inhibit colonic tumor cell growth...
  7. pmc Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
    Keqiang Zhang
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Mol Cancer 8:11. 2009
    ..Angiogenesis is critical to tumor malignancy; it plays an essential role in tumor growth and metastasis. It is important to investigate whether the angiogenic potential of tumor is affected by RRM2...
  8. pmc An overview of the rare parotid gland cancer
    Kimberley Ho
    Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA
    Head Neck Oncol 3:40. 2011
    ....
  9. pmc Mammalian target of rapamycin and head and neck squamous cell carcinoma
    Yu Min Liao
    Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
    Head Neck Oncol 3:22. 2011
    ..We have reviewed the pathogenesis of HNSCC, mTOR pathway, mTOR inhibitor and the role of mTOR in HNSCC...
  10. pmc Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer
    Stella Tommasi
    Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Breast Cancer Res 11:R14. 2009
    ....
  11. pmc Autoantibodies as potential biomarkers for breast cancer
    Li Zhong
    Department of Molecular Biology, Hebei University College of Life Sciences, 180 Wusi Road, Baoding 071002, China
    Breast Cancer Res 10:R40. 2008
    ..Antibodies to tumor-associated proteins may expand the number of available tumor markers for breast cancer and may be used together in a serum profile to enhance sensitivity and specificity...
  12. doi request reprint Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial
    Y Yen
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Am J Clin Oncol 31:317-22. 2008
    ..Oxaliplatin has recently demonstrated activity in HCC. The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin...
  13. ncbi request reprint Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial
    Yun Yen
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010 3000, USA
    Cancer Chemother Pharmacol 50:353-9. 2002
    ..We are presently developing a phase II trial of this regimen for patients with platinum-resistant head and neck cancer...
  14. ncbi request reprint Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase
    Yun Yen
    Department of Medical Oncology and Therapeutic, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    Adv Enzyme Regul 46:235-47. 2006
  15. ncbi request reprint Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma
    Yun Yen
    Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010 3000, USA
    Anticancer Res 29:4083-92. 2009
    ..2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population...
  16. pmc Early finding of chest wall metastasis of hepatocellular carcinoma in a woman by fluorodeoxyglucose-positron emission tomography scan: a case report
    Lixin Yang
    Department of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    J Med Case Reports 5:147. 2011
    ..abstract:..
  17. ncbi request reprint Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003
    Yun Yen
    City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Clin Cancer Res 9:4304-8. 2003
  18. ncbi request reprint The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53
    Bingsen Zhou
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010, USA
    Cancer Res 63:6583-94. 2003
    ..Taken together, we conclude that UV-induced activation of p53R2 transcription and binding of p53R2 to hRRM1 to form RR holoenzyme are impaired in the p53-mutant cell line PC3...
  19. pmc Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma
    Weihua Qiu
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010 3000, USA
    Am J Pathol 165:1689-99. 2004
    ..Thus, our results provided a deeper understanding of the molecular mechanism of GADD45beta down-regulation in HCC...
  20. ncbi request reprint Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression
    Xu Li
    Department of Molecular and Clinical Pharmacology, City of Hope, Duarte, California 91010, USA
    J Biol Chem 282:36177-89. 2007
    ....
  21. ncbi request reprint Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits
    Lijun Xue
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, California 91010, USA
    Cancer Res 63:980-6. 2003
    ..Therefore, the direct interaction of p53 with p53R2 and hRRM2 and the nuclear accumulation of RR subunits after UV exposure might play a pivotal role in DNA repair...
  22. ncbi request reprint A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells
    Chunling Jiang
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, California 91010, USA
    Anticancer Res 27:3783-9. 2007
    ..In this study, the synergistic effect of the histone deacetylase inhibitor depsipeptide and the DNA methyltransferase inhibitor 5-azacytidine on the Gadd45beta gene expression in human liver cells was examined...
  23. ncbi request reprint Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells
    Xiyong Liu
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Clin Cancer Res 12:6337-44. 2006
    ..The latest identified small subunit p53R2 has 80% homology to hRRM2. Here, we investigate the role of p53R2 in cancer invasion and metastasis...
  24. doi request reprint Redox property of ribonucleotide reductase small subunit M2 and p53R2
    Xiyong Liu
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA, USA
    Methods Mol Biol 477:195-206. 2008
    ..Our findings suggest that p53R2 may play a key role in defending oxidative stress by scavenging ROS, and this antioxidant property is also important for its enzymatic activity...
  25. ncbi request reprint Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor
    Shenxian Qian
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Oligonucleotides 15:1-11. 2005
    ..Our data indicate that FGFR3 is an important cell survival and antiapoptotic factor for MM cells and that ribozyme-targeted downregulation of FGFR3 might be useful as a novel therapeutic intervention in MM characterized by t(4;14)...
  26. ncbi request reprint Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment
    Agnes Juhasz
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Oncol Rep 15:1299-304. 2006
    ..Furthermore this assay may assess whether WBC samples are an appropriate surrogate tissue for approximating target down-regulation in the tumor...
  27. ncbi request reprint SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone
    Vincent Chung
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Mol Cancer Ther 5:533-40. 2006
    ....
  28. ncbi request reprint Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells
    Bingsen Zhou
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Anticancer Res 22:1369-77. 2002
    ..The subsequent depletion of dNTP pools allows for increased incorporation of dFdCTP into cells arrested in S-phase, resulting in higher levels of cytotoxicity than either treatment alone...
  29. ncbi request reprint Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer
    Xiyong Liu
    Clinical and Molecular Pharmacology Department, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Clin Colorectal Cancer 6:374-81. 2007
    ..Furthermore, hRRM2 enhanced cancer cells to induce the cell migration of Human Umbilical Vein Endothelial Cells, but p53R2 reduced this ability in transfectants...
  30. pmc An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone
    Xiyong Liu
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010 3000, United States
    Biochem Pharmacol 73:1927-38. 2007
    ..In summary, an increase of CCOX activity and free ATP level may reduce the transport, metabolism and DNA incorporation of Gem, resulting in Gem resistance...
  31. pmc Suppression of nonhomologous end joining repair by overexpression of HMGA2
    Angela Y J Li
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Cancer Res 69:5699-706. 2009
    ..In summary, a novel role for HMGA2 to interfere with NHEJ processes was uncovered, implicating HMGA2 in the promotion of genome instability and tumorigenesis...
  32. ncbi request reprint Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues
    Bingsen Zhou
    Department of Molecular and Clinical Pharmacology, City of Hope National Medical Center, Duarte, California
    Hybridoma (Larchmt) 25:264-70. 2006
    ..We propose that IHC with this monoclonal anti-hRRM2 antibody may be useful for ribonucleotide reductase research and as a biomarker for tumorgenesis...
  33. pmc Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma
    Weihua Qiu
    Department of Medical Oncology and Therapeutic Research, Gastrointestinal Disease, Pathology, and Biostatistics, City of Hope National Medical Center, Duarte, California 91010, USA
    Am J Pathol 162:1961-74. 2003
    ..05). Thus, the results of our study suggest that GADD45beta, which is down-regulated in most cases of HCC, remains an ideal candidate for development as a molecular marker in the diagnosis of HCC and as a potential therapeutic target...
  34. ncbi request reprint Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone
    Xiyong Liu
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010 3000, USA
    Biochem Pharmacol 67:1499-511. 2004
    ..This finding was consistent with enhanced NF-Y transactivation in KBGem. In summary, upregulation of NF-Y transactivation increased hRRM2 transcription, which played a pivotal role in the Gem resistant KB clone...
  35. ncbi request reprint In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase
    Jimin Shao
    Departments of Medical Oncology and Therapeutic Research and Bioinformatics, City of Hope National Medical Center, Duarte, California 91010, USA
    Cancer Res 64:1-6. 2004
    ..The susceptibility differences to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment...
  36. ncbi request reprint Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics
    Robert J Morgan
    Division of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California 91010, USA
    Clin Cancer Res 9:5896-901. 2003
    ..The purpose of this Phase I study was to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of i.p. docetaxel and to determine the peritoneal pharmacokinetics and pharmacological advantage of this agent...
  37. pmc ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage
    Lufen Chang
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Proc Natl Acad Sci U S A 105:18519-24. 2008
    ..Our results strongly suggest a novel mechanism for the regulation of p53R2 activity via ATM-mediated phosphorylation at Ser(72) and MDM2-dependent turnover of p53R2 dephosphorylated at the same residue...
  38. ncbi request reprint Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2
    Peiguo G Chu
    Division of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Am J Surg Pathol 29:359-67. 2005
    ..MUC2+/CDX2+ can be used as positive markers for the intestinal-type adenocarcinoma of duodenal papillary origin with a positive predictive value of 82%...
  39. ncbi request reprint Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy
    George Somlo
    Department of Medical Oncoilogy and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    J Clin Oncol 22:1839-48. 2004
    ..Tumor- and treatment-related factors were analyzed to generate a prognostic model...
  40. ncbi request reprint A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
    Yun Yen
    City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Cancer Chemother Pharmacol 54:331-42. 2004
    ..A phase I trial was initiated to determine the safety profile and maximum tolerated doses of 3-AP and gemcitabine when used in combination in patients with advanced cancer...
  41. pmc Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study
    Stephen I Shibata
    Department of Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 64:1149-55. 2009
    ..It was combined with oxaliplatin and capecitabine in a phase I trial in patients with advance solid tumors based on previous studies demonstrating potentiation of chemotherapy with ribonucleotide reductase inhibitors...
  42. ncbi request reprint Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells
    Min Guan
    Department of Clinical Molecular Pharmacology, Division of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, 91010, USA
    Anticancer Res 29:1-9. 2009
    ..In this study, we investigated whether the therapeutic effect of bortezomib is associated with FGFR3 expression...
  43. ncbi request reprint Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 54:283-9. 2004
    ....
  44. ncbi request reprint Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies
    Warren A Chow
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 54:241-8. 2004
    ..Since delivery of doxorubicin by 96-h continuous intravenous infusion also reduces cardiac injury, we studied delivering dexrazoxane and doxorubicin concomitantly by prolonged intravenous infusion...
  45. pmc Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2
    Bingsen Zhou
    Department of Molecular Pharmacology, City of Hope National Medical Center, Duarte, California 91010, USA
    Mol Cancer Ther 9:1669-79. 2010
    ....
  46. ncbi request reprint Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors
    Thehang Luu
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Anticancer Res 30:167-74. 2010
    ..Bortezomib demonstrates synergism with gemcitabine via a fixed-dose rate (FDR). The aim of this phase I trial in solid tumors was to establish the maximum tolerated dose (MTD) and safety data for this combination...
  47. ncbi request reprint Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma
    Lijun Zhu
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Mol Cancer Ther 4:787-98. 2005
    ..Our observations indicate that shRNAs can specifically and effectively inhibit FGFR3 expression. This targeted approach may be worth testing in multiple myeloma patients with t(4;14) and FGFR3 overexpression in the future...
  48. ncbi request reprint Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy
    Gary Guishan Xiao
    Department of Clinical and Molecular Pharmacology, City of Hope National Cancer Center, Duarte, CA 91010 3000, USA
    Cancer Genomics Proteomics 5:151-60. 2008
    ..The increased specificity due to the anti-resistance effect of GTI-2040 may also lead to a more favorable therapeutic outcome...
  49. ncbi request reprint A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression
    Stephen Shibata
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 59:549-57. 2007
    ..Preclinically, gemcitabine has demonstrated synergy when combined with platinum compounds. These facts formed the rationale for determining the maximum tolerated dose (MTD) of gemcitabine in combination with oxaliplatin...
  50. ncbi request reprint Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Cancer Chemother Pharmacol 51:459-64. 2003
    ....
  51. ncbi request reprint Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits
    Weihua Qiu
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Biochem Biophys Res Commun 340:428-34. 2006
    ..Taken together, the eukaryotic expression system RR holoenzyme will provide a very useful tool to understand the molecular mechanisms of RR activity and the interactions of its subunits...
  52. ncbi request reprint Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA
    Clin Cancer Res 13:1232-7. 2007
    ..To determine the maximally tolerated dose, toxicity, and pharmacokinetics of i.p. gemcitabine...
  53. ncbi request reprint The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells
    Tieli Wang
    Department of Chemistry, California State University, Carson, California 90072, USA
    Cancer Res 65:10338-46. 2005
    ....
  54. pmc The induction of growth arrest DNA damage-inducible gene 45 beta in human hepatoma cell lines by S-adenosylmethionine
    Weihua Qiu
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Am J Pathol 171:287-96. 2007
    ..Thus, our results suggest that GADD45beta induction by SAMe via NF-kappaB may represent a novel mechanism of SAMe-mediated hepatoprotection, with p53 playing an important role...
  55. ncbi request reprint Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer
    Kim A Margolin
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 11:903-11. 2005
    ..The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT...
  56. ncbi request reprint Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products
    Agnes Juhasz
    Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    J Clin Lab Anal 17:184-94. 2003
    ..By allowing the measurement of intratumoral target gene expression, these new methods may prove useful in predicting the clinical utility of gemcitabine- and platinum-containing chemotherapy programs in patients with solid tumors...
  57. doi request reprint Symptom concerns and quality of life in hepatobiliary cancers
    Virginia Sun
    Department of Nursing Research and Education, City of Hope, Duarte, CA, USA
    Oncol Nurs Forum 35:E45-52. 2008
    ..To describe the symptom concerns of patients with hepatocellular carcinoma (HCC) and pancreatic cancer and explore the effect of symptoms on patients' quality of life (QOL)...
  58. ncbi request reprint Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma
    Wei hua Qiu
    City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA
    World J Gastroenterol 11:5266-72. 2005
    ..To describe the significant over-expression of fibroblast growth factor receptor 3 (FGFR3), which is a signal transduction and cell proliferation related gene in hepatocellular carcinoma (HCC)...
  59. pmc Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
    Robert J Morgan
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA
    Cancer Chemother Pharmacol 66:927-33. 2010
    ....
  60. pmc Alternative splicing as a therapeutic target for human diseases
    KENNETH J DERY
    Division of Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA
    Methods Mol Biol 555:127-44. 2009
    ..These strategies are likely to continue to play an integral role in studying gene function and drug discovery...
  61. ncbi request reprint Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity
    Frank Un
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA 90101, USA
    Anticancer Res 26:2761-7. 2006
    ..ICBP90 (overexpressed in breast cancer) is a novel Rb-associating transactivator for the human topoisomerase IIalpha gene and responds to DNA damage-induced checkpoint signaling...
  62. ncbi request reprint A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase
    Jimin Shao
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA
    Mol Cancer Ther 5:586-92. 2006
    ..These results indicate that Triapine-induced inhibition of ribonucleotide reductase is caused by ROS. We suggest that ROS may ultimately be responsible for the pharmacologic effects of Triapine in vivo...
  63. ncbi request reprint Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation
    Lijun Xue
    Department of Clinical and Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Cancer Res 67:16-21. 2007
    ..On the other hand, the ribonucleotide reductase activity increases at the corresponding time in response to UV. These data suggest a new function of p53R2 of cooperating with p21 during DNA repair at G(1) arrest...
  64. pmc Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models
    Tontanai Numbenjapon
    Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute at City of Hope, City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Clin Cancer Res 15:4365-73. 2009
    ..Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11...
  65. ncbi request reprint Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay
    Jimin Shao
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010, USA
    Biochem Pharmacol 69:627-34. 2005
    ..We suggest that this novel recombinant-holoenzyme-based in vitro assay is a useful tool for the discovery of more potent and subunit-selective inhibitors of RR...
  66. doi request reprint Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry
    Wanda M P Coston
    Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Am J Surg Pathol 32:433-44. 2008
    ..GPC3 immunoreactivity, in combination with a complete CD34 immunostaining pattern, greatly facilitates the accuracy of distinguishing between malignant hepatic lesions and benign mimickers...
  67. ncbi request reprint The ribonucleotide reductase subunit M2B subcellular localization and functional importance for DNA replication in physiological growth of KB cells
    Xiyong Liu
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010 3000, USA
    Biochem Pharmacol 70:1288-97. 2005
    ..Thus, our findings suggested that M2B might play an important role for initiating DNA replication of KB cells in normal growth...
  68. ncbi request reprint Intrahepatic cholangiocarcinoma and hepatitis: case study and literature review
    Frank Luh
    Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Anticancer Res 29:3239-43. 2009
    ..The patient also had a strong family history of cancer. Finally, we attempt to review some of the important developments in the study of ICC, with particular attention to recent studies linking hepatitis with the disease...
  69. ncbi request reprint Structurally dependent redox property of ribonucleotide reductase subunit p53R2
    Lijun Xue
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, California 91010, USA
    Cancer Res 66:1900-5. 2006
    ..Our findings suggest that p53R2 may play a key role in defending oxidative stress by scavenging ROS, and this antioxidant property is also important for its fundamental enzymatic activity...
  70. ncbi request reprint Paraneoplastic syndromes in cancer: Case 3. Parathyroid hormone-related hypercalcemia in cholangiocarcinoma
    Yun Yen
    Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA
    J Clin Oncol 22:2244-5. 2004
  71. pmc p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest
    Keqiang Zhang
    Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Mol Cancer Ther 10:269-78. 2011
    ....

Research Grants8

  1. Drug Development of Ribonucleotide Reductase Inhibitor
    Yun Yen; Fiscal Year: 2010
    ..COH20 represents a unique inhibitor that accomplishes the task of higher antitumoral activity as well as establishing a new drug design in developing RR inhibitors for the future. ..
  2. Genetic Basis of Colon Adenoma Synchronous to Carcinoma.
    Yun Yen; Fiscal Year: 2005
    ..We will understand better the biology of different subsets of sporadic CRC, namely CRC+SA, proximal tumors and MSI instable tumors. Our findings will impact on future clinical therapeutic studies of CRC. ..
  3. The Role of RR in Chemotherapeutic Drug Resistance
    Yun Yen; Fiscal Year: 2005
    ..Taken together, our proposed studies will provide an integrated evaluation of the molecular control of RR-mediated chemotherapeutic drug resistance. ..